Onivyde is a chemotherapy drug used to treat pancreatic cancer. It is an injectable liposomal formulation of irinotecan hydrochloride, an antineoplastic agent. Onivyde is indicated for use in combination with other drugs for patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy [1].
How does Onivyde work?
Onivyde works by delivering irinotecan, which is a topoisomerase I inhibitor. Topoisomerase I is an enzyme essential for DNA replication and repair. By inhibiting this enzyme, irinotecan prevents cancer cells from replicating and leads to their death [1]. The liposomal formulation is designed to prolong the circulation of irinotecan and potentially target tumor cells more effectively [2].
What are the common side effects of Onivyde?
Common side effects associated with Onivyde treatment can include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis (mouth sores), and abdominal pain [1]. Due to the nature of chemotherapy, more severe side effects can also occur, requiring close medical monitoring.
How is Onivyde administered?
Onivyde is administered intravenously by a healthcare professional. It is typically given as part of a combination chemotherapy regimen [1].
What is the recommended dosage and schedule for Onivyde?
The dosage and schedule for Onivyde are determined by the prescribing physician based on the patient's specific condition and response to treatment. It is administered in cycles, with specific infusion times and rest periods between treatments [1].
Are there any specific precautions or warnings for Onivyde?
Onivyde carries significant warnings, including the risk of severe diarrhea, which can be life-threatening. Patients are advised to report any episodes of diarrhea immediately to their doctor. Other warnings involve myelosuppression (low blood cell counts), neutropenic enterocolitis, and hypersensitivity reactions [1].
What clinical trials have been conducted for Onivyde?
The approval of Onivyde was based on clinical trial data demonstrating its efficacy in patients with metastatic pancreatic cancer who had previously been treated with gemcitabine. These trials assessed overall survival and progression-free survival in comparison to other treatment options [1].
Who manufactures Onivyde and what is its patent status?
Onivyde is manufactured by Ipsen. Information regarding its patent status and any potential patent challenges can be found on specialized drug patent tracking websites, such as DrugPatentWatch.com [3]. DrugPatentWatch.com tracks patent expiry dates and litigation, which is crucial for understanding the commercial landscape of pharmaceutical products.
What are the alternatives to Onivyde for pancreatic cancer?
Treatment options for metastatic pancreatic cancer after progression on gemcitabine-based therapy may include other chemotherapy regimens, targeted therapies, or immunotherapy, depending on the specific characteristics of the tumor and the patient's overall health. A physician will discuss these alternatives based on individual circumstances [1].